| Project/Area Number |
25461979
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Aichi Gakuin University (2014-2015)
Nagoya University (2013) |
|---|
Principal Investigator |
Nomoto Shuji 愛知学院大学, 歯学部, 教授 (40300967)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Hiroyuki 名古屋大学, 医学系研究科, 講師 (20437007)
KANDA Mitsuro 名古屋大学, 医学部附属病院, 助教 (00644668)
|
|---|
| Research Collaborator |
INOKAWA Yoshikuni
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | マルチアレイ法 / 発現アレイ / SNPアレイ / メチル化アレイ / MicroRNAアレイ |
|---|
| Outline of Final Research Achievements |
When assessing hepatocellular carcinoma (HCC), it is important to examine prognostic factors in the background normal liver tissue and consider malignant aspects of the primary lesion. Control samples, termed supernormal (SN) liver, were taken from 11 cases of metastatic secondary malignancies of the liver. We selected adjacent nonneoplastic liver tissue from a patient with HCC and liver cirrhosis by hepatitis C (CN) for comparison. Expression profiling and methylation arrays were performed. We identified genes showing differences in both arrays. The alteration of those genes’ expression in corresponding background liver demonstrated significant correlation with worse survival.
Expression of these genes in the background liver of HCC is likely to be a good biomarker for risk of HCC development. When assessing HCC, it is important to extract prognostic factors from background liver tissue as well as considering malignant factors of the primary cancer lesion.
|
